BPC-157 is also known as Body Protection Compound 157, Bepecin, Pentadecapeptide BPC-157, and PL-10
Their small, linear structures facilitate easier synthesis, high water solubility, and effective diffusion across biological barriers
Preexisting health conditions Conditions like diabetes, gastrointestinal issues, or B12 deficiency may require dosage modifications for safety and effectiveness
Stacking them addresses both substrate metabolism and cofactor availability
Disclosure of interest: Xiao Wang: nothing to disclose E-Posters - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.03 - EPIDEMIOLOGY & RISK FACTORS P2515 - ESOC25-1203 GUT MICROBIOTADEPENDENT TRIMETHYLAMINE N-OXIDE AND COGNITIVE FUNCTION OVER THREE YEARS AFTER MILD-TO MODERATE ISCHEMIC STROKE - PROSCIS B Thomas Liman 1 , Naomi Giesers 2 , Arash Haghikia 3 , Ulf Landmesser 4 , Stanley Hazen 5 , Matthias Endres 6 1 University of Oldenburg, Charit Universittsmedizin Berlin, Oldenburg, Germany, 2 University of Oldenburg, Oldenburg, Germany, 3 Ruhr University Bochum, Bochum, Germany, 4 Charit Universittsmedzin Berlin, Berlin, Germany, 5 Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, United States, 6 Charit Universittsmedizin Berlin, Dept of neurology, Berlin, Germany Background and Aims: Gut microbiotadependent metabolites, in particular trimethylamine n-oxide (TMAO) have been identified as promoters of atherosclerosis
